ERBB2 and breast cancer: (55) analyzed 1173 breast cancer patients enrolled in the TACT study and reported that extensive CIN was associated with better prognosis in patients with ER-/HER2- breast cancer (P = 0.03 and 0.007, respectively), indicating that CIN is a good prognostic marker of breast cancer.